Department of Internal Medicine, Endocrinology and Diabetology, Central Clinical Hospital MSWiA, Warszawa, Poland.
Endokrynol Pol. 2011 Jan-Feb;62(1):79-83.
Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases. Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for patients can definitely be confirmed.
地舒单抗是一种人源化单克隆抗体的国际通用名，获批用于治疗骨质疏松症。该抗体与核因子κB 受体活化因子配体（RANKL）结合，使其失活。结果，破骨细胞的形成和存活受到抑制，导致其凋亡。所有这些导致较低的骨吸收，同时骨矿物质密度（BMD）增加。地舒单抗还降低了椎体和非椎体骨折的风险。该药物在肾功能损害的各个阶段同样有效；它不影响骨折愈合过程，也不会导致高心血管风险患者的动脉粥样硬化进展。在 FREEDOM 研究中对不良反应进行分析后（该研究表明，地舒单抗使用过程中观察到的大多数不良反应的发生率与安慰剂组相似），可以明确其对患者的安全性。
